Comparative Pharmacology
Head-to-head clinical analysis: LOW OGESTREL 21 versus NORLESTRIN 28 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW OGESTREL 21 versus NORLESTRIN 28 1 50.
LOW-OGESTREL-21 vs NORLESTRIN 28 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive